Open AccessPB2449 RED CELL ALLOIMMUNIZATION IN MULTITRANSFUSED ONCOLOGY PATIENTS
Author(s) -
Mahesar A.
Publication year - 2019
Publication title -
hemasphere
Language(s) - Slovenian
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000568256.47033.e1
Subject(s) - medicine , abo blood group system , isoantibodies , population , blood transfusion , transfusion therapy , antibody , rh blood group system , immunology , environmental health
Background: Blood transfusion is common nowadays in management of various diseases especially oncology patients. Blood grouping and cross matching is done in routine practice before transfusion against Major blood groups (i.e., ABO & Rh blood groups). Alloantibodies can be produced against Minor blood groups. These Alloantibodies can cause acute or delayed hemolytic transfusion reactions. These hemolytic reactions cause anemia as well as other related complications. Oncology patients can produce alloantibodies because of multiple transfusions from different donors. Pre transfusion antibody screening and identification in oncology patients can help them from unnecessary time required for identification of proper cross matched donor. Alloantibody identification can prevent the patients from complications related to allogenic blood transfusion. This study is designed to determine the frequency of alloantibodies in multitransfused oncology in Pakistani population. Aims: The objectives of the study is to determine the frequency and types of RBC alloimmunization in multitransfused oncology patients at a teaching hospital in Lahore, Pakistan. Methods: A total of 145 cases fulfilling the inclusion and exclusion were selected by non probability purposive sampling. Blood sample was taken and Plasma was separated with centrifugation. Routine blood testing for ABO and Rh grouping was done. The patient's plasma that was positive on initial screening for alloimmunization was further tested with Antibody Identification Panel. Results: The frequency of Red cell alloimmunization is 5.5% (8/145). The alloantibodies for Rh were 6 (4.13%) and one patient positive each for Kell and Duffy having frequency of 0.68 % each. Alloantibodies are found to be Anti‐D four (4) and each one (1) Anti‐ C, Anti‐E, Anti‐K and Anti Fya Summary/Conclusion: Allo‐antibodies are produced against Minor blood groups in multitransfused oncology patients. Alloantibodies against Rh system were most frequent.